During the past decade, Virginia Cancer Institute ( Site 0052) conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Virginia Cancer Institute ( Site 0052)" are "Prostatic Neoplasms" (3 trials). Many other conditions were trialed in "Virginia Cancer Institute ( Site 0052)" in a lesser frequency.

Most popular intervention types in "Virginia Cancer Institute ( Site 0052)" are "Biological" (3 trials) and "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (3 trials), "Enzalutamide" (2 trials), "Placebo" (2 trials), "Prednisone" (2 trials) and "Abiraterone acetate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Cancer Institute ( Site 0052)" are 3 trials for "Male" genders.

Currently, there are NaN active trials in "Virginia Cancer Institute ( Site 0052)". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Virginia Cancer Institute ( Site 0052), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Cancer Institute ( Site 0052), 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".